Stock Events

Stock Events

Search...

Novartis

CHF99.47

1310

+CHF0.7+0.71% Friday 15:31

Statistics

Day High

99.79

Day Low

98.67

52W High

100.96

52W Low

81.63

Volume

2,395,540

Avg. Volume

2,998,431

Mkt Cap

195.55B

P/E Ratio

23

Dividend Yield

3.27%

Dividend

3.26

Upcoming

Dividend Payment

Dividend Payment

Dividends

3.27%Dividend Yield

10Y Growth

3.05%

5Y Growth

5.7%

3Y Growth

5.23%

1Y Growth

9.67%

Earnings

29OctConfirmed

Q1 2023

Q2 2023

Q3 2023

Q4 2023

Q1 2024

Q2 2024

Next

1.72

1.88

2.05

2.22

Expected EPS

1.886795

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NOVN.SW. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Pfizer competes directly with Novartis in various therapeutic areas, including cardiovascular, oncology, and immunology.

Johnson & Johnson

Johnson & Johnson, through its pharmaceutical segment, competes in areas such as immunology and oncology, similar to Novartis.

Merck is a key competitor in the oncology sector, directly competing with Novartis' cancer treatments.

Roche competes closely with Novartis, especially in oncology and ophthalmology, with both companies headquartered in Switzerland.

AbbVie competes in the immunology and oncology markets, areas where Novartis has significant investments.

GlaxoSmithKline competes with Novartis in respiratory, vaccines, and HIV, areas where Novartis has presence or interest.

Bristol-Myers Squibb

Bristol Myers Squibb is a competitor in the oncology and cardiovascular markets, directly competing with Novartis' drug portfolio.

Sanofi competes with Novartis in areas such as vaccines, oncology, and cardiovascular diseases.

AstraZeneca competes in the oncology, cardiovascular, and respiratory sectors, overlapping with Novartis' interests.

Amgen competes with Novartis in the biopharmaceutical sector, particularly in treatments for bone diseases, cancer, and cardiovascular diseases.

About

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Show more...

CEO

Dr. Vasant Narasimhan M.D.

Employees

76057

Country

CH

ISIN

CH0012005267

WKN

000904278

Listings